Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK2251052

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens
ABSTRACT The emergence of multidrug-resistant (MDR) Gram-negative bacilli is a major concern in the treatment of nosocomial… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus
ABSTRACT GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in… Expand
  • figure 1
Highly Cited
2014
Highly Cited
2014
Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections
ABSTRACT GSK2251052, a novel leucyl-tRNA synthetase (LeuRS) inhibitor, was in development for the treatment of infections caused… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2013
2013
Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms
ABSTRACT We studied the comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916… Expand
  • table 1
  • table 2
  • table 2
2013
2013
Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
2013
2013
Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial.
GSK2251052 is a boron-containing antimicrobial agent in clinical development for the treatment of serious Gram-negative bacterial… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
2013
2013
Intrapulmonary Pharmacokinetics of GSK2251052 in Healthy Volunteers
ABSTRACT The plasma and intrapulmonary pharmacokinetics (PK) of intravenous (i.v.) GSK2251052, a novel boron-containing… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
2013
2013
Disposition and Metabolism of GSK 2251052 in Humans : A Novel Boron-Containing Antibiotic s
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro2,1-benzoxaborole (GSK2251052) is a novel boron-containing… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
2013
2013
Intrapulmonary pharmacokinetics of GSK 2251052 in Healthy Volunteers
10 Running Title: Pulmonary and Plasma PK of GSK2251052 11 12 13 # Corresponding author: Parul Patel, Pharm.D. 14 GlaxoSmithKline… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
2011
2011
GSK2251052, a Novel Boron-containing Protein Synthesis Inhibitor, with Comparative in vitro Activity against Pseudomonas aeruginosa from a Global Population
Background: GSK2251052 (formerly AN3365), a novel boron-containing leucyl-tRNA synthetase inhibitor with in vitro activity… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE